Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals

The agreement gives Tata the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain
Obese man
China (46mln) and India (30mln) rank second and third in having the highest number of overweight people in the world

Life sciences group OptiBiotix Health plc (LON:OPTI) has signed a manufacturing agreement with India-listed food ingredients giant Tata Chemicals.

It is an expansion of a deal the two inked last December and gives Tata, part of the Tata Group, the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain.

WATCH: Opti boss on 'very good' deal with Tata

READ: Opti partners up with multinational as it targets Asian weight loss markets

The sugar – galacto-oligosaccharide – will be used in various food and over-the-counter products, subject to its successful development at pilot development.

When digested they stimulate the growth of ‘good’ gut bacteria, which Opti has showed can lead to improved health and help to tackle ‘chronic lifestyle diseases’ such as diabetes and obesity.

This agreement with Tata focuses on the Asian markets, particularly India, but Opti is in talks with other companies about manufacturing the cholesterol and blood pressure-lowering strain in other markets such as the US.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US soon

“We believe the combination of OptiBiotix's ability to develop ingredients which can modify an individual's microbiome, and Tata's research and manufacturing expertise, international reputation, and global reach, places both companies at the forefront of global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“This agreement takes both companies further down the path of translating the science of the microbiome field into products which will improve the health and wellbeing of people around the world.”

City broker praises 'interesting' deal

"The announcement is interesting in that TATA recently launched its own GOS related first general health product and is a major supplier of pharmaceutical industries both within India and globally," said finnCap analyst Lorne Daniel.

"Whilst only in the earliest stages of development, we are encouraged by this announcement and continue to recognise the commercial milestones that OPTI's management are steadily and reliably delivering upon."

Shares rose 5.35%, or 3.8p, to 74.8p.

--Updates for broker comment, video link and share price--

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use